Tag

Advertisement

BioInvent

Sylvie Ryckebusch

BioInvent appoints Chief Business Officer

June 9, 2022

BioInvent International has announced the …

Martin Welschof

BioInvent’s BI-1206 to advance into expansion stage of Phase 1/2a study

May 13, 2022

BioInvent International has announced its …

Martin Welschof

BioInvent receives milestone payment

May 5, 2022

BioInvent International receives a milestone …

Marie Moores

BioInvent appoints new Chief Operating Officer

February 20, 2022

BioInvent International has announced the …

Martin Welshof

BioInvent granted Orphan Drug Designation by the FDA

February 1, 2022

BioInvent International has announces that …

Martin Welschof

BioInvent shows further positive clinical data

November 7, 2021

BioInvent International has announced additional …

Martin Welschof

BioInvent enters clinical trial collaboration

August 11, 2021

BioInvent International has entered into …

Martin Welschof

BioInvent receives IND approval

April 8, 2021

The U.S. Food and Drug …

Martin Welschof

BioInvent carries out a directed share issue of USD 116 million

February 23, 2021

The company plans to in …

Martin Welschof

BioInvent streamlines agreement on its BI-1206 antibody

January 12, 2021

BioInvent International has restructured a …

Martin Welschof

BioInvent and Cantargia sign manufacturing agreement

December 11, 2020

Cantargia and BioInvent International have …

Martin Welschof

BioInvent enters licensing agreement for Greater China region

October 28, 2020

BioInvent International and CASI Pharmaceuticals, …

Martin Welschof

BioInvent completes directed share issue of 487 million SEK

June 11, 2020

The Board of Directors of …

Björn Frendeus

BioInvent presents promising results and expands anti-TNFR2 program

May 15, 2020

BioInvent International has announced the …

Bioinvent

New clinical data from BioInvent

June 18, 2019

The company has announced the …

Mikael Oredsson

BioInvent and Transgene collaborate

December 7, 2017

BioInvent International and Transgene have …

1
2
3